Company Overview of AbGenomics International, Inc.
AbGenomics International, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer and immune related inflammatory diseases. It offers AbGn-168, an immunomodulating investigational therapeutic antibody against CD162 that induces apoptosis of late-stage activated T cells and other immune cells, as well as spare naive, regulatory, and memory T cells; various animal disease models, such as CIA, NOD, and allergy, as well as transplantation rejection/GVHD in murine and DTH in non-human primate; and autoimmune diseases, including rheumatoid arthritis, Crohn's disease, lupus, and psoriasis. The company also provides antibody-7 ...
4984 El Camino Real
Los Altos, CA 94022
Founded in 2000
Key Executives for AbGenomics International, Inc.
Director of IP Management & Quality Assurance
Director of Project & Alliance Managements
Compensation as of Fiscal Year 2014.
AbGenomics International, Inc. Key Developments
AbGenomics International, Inc. Presents at BioPharm America 2013, Sep-18-2013 03:15 PM
Aug 13 13
AbGenomics International, Inc. Presents at BioPharm America 2013, Sep-18-2013 03:15 PM. Venue: Westin Boston Waterfront Hotel, Boston, Massachusetts, United States.
AbGenomics International, Inc. Raises $9.6 Million in Financing
Jul 17 13
AbGenomics International, Inc. has raised $9.6 million in a financing round in private placement.
AbGenomics International, Inc. Obtains FDA Agreement on its Phase 2 Clinical Trial Plans
Aug 17 12
AbGenomics International, Inc. announced that it has obtained agreement from U.S. Food and Drug Administration for its proposed plans for a phase 2 clinical trial of the novel autoimmune therapeutic candidate, AbGn-168H. Antibody demonstrated a great safety profile in preclinical safety and phase 1 clinical trial studies in both psoriasis patients and healthy volunteers. In SRD phase 1 psoriasis patient study, a clear biological/pharmacological effect consistent with the proposed mechanism of action of AbG's antibody was demonstrated in patients. The current Phase 2 clinical trial of AbGn-168H will be a multicenter, placebo-controlled, double-blind trial. The primary objective of the study is to demonstrate that AbGn-168H provides safe, durable, and remissive therapeutic effect in psoriatic patients. Additional clinical trials for type-I diabetes, Crohn's and other autoimmune diseases are under evaluation.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|